Bioxcel Therapeutics Stock News

NEW HAVEN, Conn., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop tran

BioXcel Therapeutics Inc (BTAI) shares closed today 12.3% higher than it did at the end of yesterday. The stock is currently up 12.3% year-to-date, down 50.6% over the past 12 months, and up 107.0% over the past five years. Today, the Dow Jones Industrial Average rose 0.6%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $22.94 and as low as $19.66 this week.Shares closed 66.3% below its 52-week high and 22.0% above its 52-week low.Trading volume this week was 59.0% higher than the 10-day average and 56.6% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance over the past 12 months lags the peer average by 62.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

NEW HAVEN, Conn., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transf

Two Phase 3 studies to enroll a total of 300 patients in assisted living or residential facilities and nursing homes to evaluate the safety and efficacy of BXCL501

Two Phase 3 studies to enroll a total of 300 patients in assisted living or residential facilities and nursing homes to evaluate the safety and efficacy of BXCL501

The FDA extended BTAI's PDUFA by three months, tanking the stock.

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update FDA Review of BXCL501 Extended to April 5, 2022 On December 1, 2021, BioXcel Therapeutics, Inc. (NASDAQ:

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update PDUFA Data of Jan. 5, 2022 for BXCL501; MAA Filing Expected in 1H22 In May 2021, BioXcel Therapeutics, Inc. (NASDAQ:

In last trading session, BioXcel Therapeutics Inc. (NASDAQ:BTAI) saw 1.0 million shares changing hands with its beta currently measuring 0.94. Company’s recent per share price level of $20.43 trading at -$2.5 or -10.90% at ring of the bell on the day assigns it a market valuation of $561.62M. That closing price of BTAI’s stock is … BioXcel Therapeutics Inc. (NASDAQ:BTAI) Decline -10.90%, More Rally Possible Read More »

A regulatory delay is weighing on the biotech today.

A regulatory delay is weighing on the biotech today.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI)s share price gapped down prior to trading on Wednesday . The stock had previously closed at $22.93, but opened at $17.31. BioXcel Therapeutics shares last traded at $19.91, with a volume of 3,915 shares trading hands. Several equities analysts have commented on the company. Berenberg Bank reiterated a buy rating and []

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir The Food and Drug Adminis

(RTTNews) - BioXcel Therapeutics, Inc. (BTAI) said the FDA has extended the PDUFA date for its review of the New Drug Application of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II. The company responded to the information request by FDA pertaining to analyses of clinical data, and was